HEMOSTEMIX
Hemostemix Inc., a clinical-stage biotechnology company, develops, manufactures, and commercializes blood-derived cell therapies for medical conditions in Canada. It develops cell therapy products from the patient’s own blood, a relatively non-invasive source of therapeutic cells. The company’s lead product is ACP-01, which is in Phase II clinical trial for the treatment of critical limb ischemia. It is also developing various types of cells products, such as bone cell precursors, myocardial cell precursors, and neural cell precursors.
HEMOSTEMIX
Industry:
Biotechnology Clinical Trials Therapeutics
Founded:
2006-01-01
Address:
Blackfalds, Alberta, Canada
Country:
Canada
Website Url:
http://www.hemostemix.com
Total Employee:
1+
Status:
Active
Contact:
403 471 6665
Email Addresses:
[email protected]
Total Funding:
11.26 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Google Font API Google Analytics LetsEncrypt Apple Mobile Web Clips Icon Google Tag Manager WordPress
Similar Organizations
Abivax
Abivax is a pioneering biotech company.
Origin
Origin is a privately held, clinical-stage biotechnology company.
ArsenalBio
ArsenalBio is a programmable cell therapy company that offers advanced CAR T-cell therapies for solid tumors.
Atavistik Bio
Atavistik Bio is a pre-clinical biotechnology company.
Atom Bioscience & Pharmaceutical
Atom Bioscience is a clinical-stage biotechnology company.
Biorem Inc.
Biorem is a pioneer environmental biotechnology company.
Calimmune
Calimmune is a clinical-stage gene therapy company.
Cardurion Pharmaceuticals
Cardurion is a Boston-based cardiovascular biotechnology company
Cellenkos
Cellenkos is a clinical stage biotech company.
Cocrystal Pharma
Cocrystal Pharma, Inc. is a clinical stage biotechnology company discovering and developing novel antiviral therapeutics.
EpicentRx Inc
EpicentRx Inc is a clinical-stage immuno-oncology company.
ExCellThera
ExCellThera is an advanced clinical stage biotechnology company.
IconOVir Bio
IconOVir Bio is a preclinical-stage biotechnology company.
ImmuneID
ImmuneID is a precision immunology company.
Immunicom
Immunicom is a biotechnology company.
IMV
IMV is a clinical-stage immuno-oncology company.
January Therapeutics
January Therapeutics is a San Diego-based biotechnology company.
KBP Biosciences
A multinational clinical stage biotechnology company.
Lion TCR
Lion TCR is a clinical-stage biotechnology company.
MaveriX Oncology
MaveriX Oncology is a globally-orientated biotechnology company.
Nano Cures
Nano Cures is clinical-stage biotechnology and infectious disease immunity platform company.
NovaBiotics
NovaBiotics Ltd is a clinical-stage biotechnology company.
Ocugen
Ocugen is a clinical stage biopharmaceutical company.
Oerth Bio
Oerth Bio is a agriculture-focused biotech firm.
OliX Pharmaceuticals
OliX is a clinical stage biotechnology company.
Opthea
Opthea Limited is a public Australian biotechnology company .
Origin Agritech
Origin Agritech is a leading agricultural biotechnology company.
People Corporation
People Corporation is publicly-traded on the TSX Venture Exchange under the symbol PEO.
Qualigen
Qualigen is a biotechnology company.
Relief Therapeutics
Relief Therapeutics is a clinical stage biotechnology company.
Repertoire Immune Medicines
Repertoire Immune Medicines is a clinical stage biotechnology company.
SAB Biotherapeutics
SAB Biotherapeutics is a clinical-stage biopharmaceutical development company.
SomaGenics
SomaGenics is a privately held biotechnology company.
Themis Bioscience
Themis Bioscience is a start-up biotechnology company.
Turnstone Biologics
Turnstone Biologics is a privately-held clinical stage biotech company.
Current Employees Featured
Founder
Stock Details
Investors List
Wood Capital
Wood Capital investment in Post-IPO Debt - Hemostemix
Key Employee Changes
| Date | New article |
|---|---|
| 2022-05-16 | Hemostemix Announces Rick Groome as Special Advisor to The CEO |
Official Site Inspections
http://www.hemostemix.com Semrush global rank: 7.74 M Semrush visits lastest month: 437
- Host name: host9a.ionblade.com
- IP address: 135.148.50.237
- Location: United States
- Latitude: 37.751
- Longitude: -97.822
- Timezone: America/Chicago
More informations about "Hemostemix" on Search Engine
Stem Cell Therapy for CLI - Hemostemix
Hemostemix is a clinical-stage biotechnology company focused on developing and commercializing a proprietary autologous cell therapy to treat ischemic diseases.See details»
Funding Booklet Overview - hemostemix.com
Hemostemix is a phase III clinical-stage biotechnology company focused on developingand commercializing a proprietary stem cell therapy to treat diseases caused by …See details»
Hemostemix - Crunchbase Company Profile & Funding
Details. Hemostemix Inc., a clinical-stage biotechnology company, develops, manufactures, and commercializes blood-derived cell therapies for medical conditions in …See details»
Hemostemix Announces Reorganization - Hemostemix
Hemostemix Inc. (“Hemostemix” or the “Company“) (TSX VENTURE: HEM) announces the execution of a management contractor agreement with Drive Capital Inc. (“Drive”) …See details»
Hemostemix. The Canadian Biotech that Could …
September 11, 2021 By Cade Hildreth (CEO) 2 Comments. Hemostemix Inc. (“Hemostemix”) (TSX Venture:HEM; OTCQB:HMTXF) is a publicly traded clinical-stage biotech company that develops and commercializes …See details»
Hemostemix Inc. | LinkedIn
Hemostemix is a public clinical-stage company that develops and commercializes innovative blood-derived cell therapies for medical conditions that are not adequately …See details»
Technology Platform for Developing Autologous Cell …
Hemostemix’s technology platform for developing autologous cell therapies has the potential to treat a broad range of vascular diseases. We are currently developing a treatment for critical limb ischemia (“CLI”), which …See details»
Hemostemix Announces the Incorporation of Hemostemix …
Calgary, Alberta, August 29, 2023: – Hemostemix Inc. (TSXV:HEM) (OTCQB:HMTXF) (FSE:2VF0) is pleased to announce it incorporated Hemostemix Quebec Inc. and has …See details»
Stay Up To Date With News About Hemostemix
Hemostemix Obtains all Clinical Trial Data and Announces $2.5 Million Unit Offering. The company’s principal business is to develop, manufacture and commercialize blood-derived stem cell therapies to treat various …See details»
Hemostemix Company Profile - Craft
Mar 5, 2024 Hemostemix is a biotechnology company focused on developing and commercializing a proprietary autologous cell therapy to treat ischemic diseases. ACP …See details»
News & Press Releases - Hemostemix
Oct 3, 2023 Hemostemix Announces the Incorporation of Hemostemix Quebec Inc. and $6 Million in Grant Applications Aug 14 / 2023 Hemostemix Announces Arbitration …See details»
Hemostemix Announces Updated Phase II Randomized Clinical …
Feb 6, 2024 HMTXF. Calgary, Alberta-- (Newsfile Corp. - February 6, 2024) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) ("Hemostemix" or the …See details»
Hemostemix Announces the Incorporation of Hemostemix …
Aug 29, 2023 HMTXF. Calgary, Alberta-- (Newsfile Corp. - August 29, 2023) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) is pleased to announce …See details»
Blog - Stay Up To Date - hemostemix.com
Jul 5, 2023 Calgary, Alberta, September 12, 2023: – Hemostemix Inc. (TSXV:HEM) (OTCQB:HMTXF) (FSE:2VF0) is pleased to announce its study of NCP-01 supporting …See details»
Hemostemix Announces Letter of Commitment, Non-Dilutive …
Jan 19, 2023 Hemostemix Announces Letter of Commitment, Non-Dilutive Funding Structure and $250,000 of Funding by the McGill University Health Centre Foundation. …See details»
Hemostemix Joins Centre for Commercialization of Regenerative …
May 5, 2014 Hemostemix, a clinical-stage Canadian-Israeli company that develops and commercializes innovative blood-derived therapies for severe medical conditions, is the …See details»
Get in touch with us at Hemostemix
Hemostemix Inc. TSXV:HEM. 707 7th Ave. SW, Suite 1150 Calgary, AB T2P 3H6. 905-580-4170. [email protected]. Submit Form. Have any questions or would like …See details»
Hemostemix Announces Its Intellectual Property is Back Home
May 10, 2022 Calgary, Alberta-- (Newsfile Corp. - May 10, 2022) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) (" Hemostemix " or the " Company ") is …See details»
Investor Presentation - Hemostemix
Investor Presentation – Dec 27, 2023 DownloadSee details»
Hemostemix - Funding, Financials, Valuation & Investors
Organization. Hemostemix. Connect to CRM. Summary Financials People Technology Signals & News Similar Companies. Highlights. Stock Symbol TSXV:HEM. Funding …See details»